ost hoc data from the phase 3 ULTIMATE studies (NCT03277261; NCT03277248) showed that treatment with ublituximab (Briumvi; TG Therapeutics), a recently approved therapy for relapsing forms of multiple sclerosis (MS), resulted in greater improvements in fatigue in comparison with teriflunomide (Aubagio; Sanofi).
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045